. IKDC development appears unusual in that cytokines using the interleukin (IL)-2 receptor ␤ (IL-2R ␤ ) chain but not those using the common ␥ chain ( ␥ c ) are necessary for their generation. By directly comparing 
During innate and adaptive immune responses, NK cells and DCs appear to play distinct, complementary, and synergistic roles. NK cells, by virtue of their capacity to respond without prior sensitization, can directly eliminate infected or transformed target cells and elaborate soluble factors (cytokines and chemokines) that recruit and amplify the infl ammatory response. DCs, in contrast, are the sentinels that, once activated, take up antigen, mature, and migrate to secondary lymphoid organs, where they present the processed antigen to naive T cells to initiate the adaptive immune response. In addition, DCs and NK cells can interact in a reciprocal fashion that results in the mutual activation of both types of cells (for review see reference 1 ). Mature DCs can prime NK cells to enhance their functional capacities ( 2 ) , whereas activated NK cells secrete IFN-␥ that up-regulates antigen presentation in DCs and can " edit " DC responses through the elimination of immature DCs ( 3, 4 ) . In this way, NK cells and DCs represent two highly specialized cell types that interact in a complementary fashion. This cellular strategy could provide an additional level of control, because complete immune responses would not be efficiently achieved by activation of either cell type in isolation.
Recently, the functional dichotomy of DCs and NK cells has been challenged with the Considering their curious developmental, phenotypic, and functional qualities, we have analyzed the development of " IKDC-like " cells (the CD11c lo B220 ϩ subset) using a series of C57BL/6 mice defi cient in selected cytokines and their receptors. Using mice that report expression of the NK cell -specifi c NKp46 molecule (Ncr-1 gfp/ϩ mice) ( 14 ) , we demonstrate that IKDC-like cells are developmentally related to NK cells and share their IL-15 dependence. Moreover, many of the distinguishing features of IKDC-like cells (B220, CD11c, and MHC-II expression) are inducible in NK cells. Our results challenge the view that IKDC-like cells belong to a separate DC lineage but provide evidence that the majority of these cells resemble activated NK cells.
RESULTS AND DISCUSSION
Cells expressing the IKDC-like profi le are bona fi de NK cells Cells with the CD11c lo B220 ϩ phenotype are heterogeneous, as both CD11c and B220 are expressed by B, T, and NK lymphocytes and by diverse DC subsets. By excluding CD3 ϩ and CD19 ϩ cells, the CD11c lo B220 ϩ subset has been shown to contain pDCs (NK1.1 Ϫ Ly6C ϩ ) and a novel NK1.1 ϩ CD49b ϩ subset called IKDCs ( 5, 6 ) . Previous reports detected IKDCs in Rag2 Ϫ / Ϫ ␥ c − /y mice but not in IL-2R ␤ Ϫ / Ϫ mice ( 5, 6 ). These surprising results suggested the existence of a novel il2rg -dependent but il2rb -dependent signaling pathway that promoted IKDC development. Alternatively, the absence of IKDCs in IL-2R ␤ Ϫ / Ϫ mice could have resulted from the infl ammatory syndrome that these mice develop with age ( 13 ) . To address these possibilities, we examined the CD11c lo B220 ϩ subset in Rag2 Ϫ / Ϫ mice that were defi cient or not in the ␥ c or IL-2R ␤ chains ( Fig. 1 A ) . All mice were backcrossed onto the C57BL/6 background and carried the Nkrp1c B6 allele (allowing detection by NK1.1). We found that all mice had similar absolute numbers of BM CD11c lo B220 ϩ cells but that the defi ciency in ␥ c or IL-2R ␤ completely ablated development of NK1.1 + or CD49b ϩ cells within the CD11c lo B220 ϩ subset ( Fig. 1 A ) . Analysis of splenocytes from these mice yielded similar results ( Fig. 1 B ) . To determine which IL-2R ␤ -dependent ligand was driving IKDC development, we further analyzed Rag2 Ϫ / Ϫ IL-2 Ϫ / Ϫ and Rag2 Ϫ / Ϫ IL-15 Ϫ / Ϫ mice. The CD11c lo B220 ϩ NK1.1 + subset was present in the former but not the latter (Fig. S1 , available at http://www .jem.org/cgi/content/full/jem.20071451/DC1), confi rming the essential role for IL-15 in the development of all NK1.1 ϩ cells ( 15 ) .
characterization of a hybrid cell subset called IFN-producing killer DCs (IKDCs) ( 5, 6 ) . IKDCs were characterized as CD3 Ϫ CD19 Ϫ cells with a CD11c lo B220 ϩ phenotype and were clearly distinguished from plasmacytoid DCs (pDCs) because of the absence of Ly6C (Gr-1) expression ( 5 ). CD11c lo B220 ϩ Gr-1 − cells expressed NK1.1 and CD49b in addition to other NK cell surface markers (NKG2D and Ly49 family receptors), and like DCs, they expressed co-stimulatory molecules (CD80 and CD86) and MHC class II (MHC-II) ( 5, 6 ) . Moreover, initial reports demonstrated that IKDCs possess NK cell -like cytotoxicity and inducible IFN-␥ production, as well as a DC-like ability to secrete IFN-␣ and to stimulate transgenic OVA-specifi c T cells ( 5, 6 ) . Based on these observations, IKDCs appear to represent a hybrid eff ector cell that can act both as the " assassin " (NK cells) and as the " messenger " (DCs).
Although the evidence for dual IKDC function was clearly demonstrated at the population level (i.e., in the CD11c lo B220 ϩ subset), it could not be rigorously ruled out that IKDC activities were simply the additive property of two distinct cell types that shared a CD11c lo B220 ϩ phenotype. Neither CD11c nor B220 are DC-specifi c markers, as B cells express B220 and activated B cells and CD8 T cells, and most NK cells were shown to express CD11c ( 7 -10 ) . Only a minor fraction of IKDCs was able to produce type I IFN upon stimulation in vitro ( 5 ), and direct evidence that the same cell can produce both IFN-␣ and IFN-␥ is still lacking. Moreover, recent reports have challenged the idea that IKDCs secrete IFN-␣ upon stimulation ( 11, 12 ) , suggesting that minor pDC contamination in IKDC purifi cation may have accounted for the type I IFN detected in a previous report ( 5 ) .
Concerning their development from hematopoietic precursors, IKDCs appeared to have a truly unique cytokine dependency, because they were not detected in mice lacking the IL-2R ␤ chain (required for IL-2 and IL-15 receptor function), whereas they were present in mice lacking the common ␥ chain ( ␥ c ; required for IL-2, -4, -7, -9, -15, and -21 receptors) ( 5, 6 ) , suggesting the existence of a new IL-2R ␤ -dependent, ␥ c -independent signaling pathway. Alternatively, IKDCs could also be IL-2R ␤ independent but might be missing from IL-2R ␤ Ϫ / Ϫ mice secondary to the intense infl ammatory syndrome that these mice develop ( 13 ) . Lastly, genetic background diff erences in the mice analyzed could explain the divergent results. (PMA plus ionomycin), we found that CD11c ϩ or B220 ϩ NK cells produced somewhat more IFN-␥ than CD11c Ϫ or B220 Ϫ NK cells ( Fig. 2 C ) . Collectively, these results fail to support the notion that B220 hi cells represent a distinct phenotypic and functional NK1.1 ϩ NK cell subset.
Activation-induced changes in B220, CD11c, and MHC-II expression in NK cells MHC-II expression has been proposed as a defi ning characteristic for CD11c lo B220 + IKDC-like cells ( 5 ) . Consistent with a previous report ( 5 ), few splenic NK cells (CD3 − NK1.1 ϩ ) from C57BL/6 mice expressed MHC-II molecules on their cell surface under steady-state conditions ( Fig. 3 A ) . The highest proportion of MHC-II + cells among CD3 Ϫ NK1.1 ϩ cells could be detected in the lymph nodes (10 -50%), although a subset of MHC-II ϩ NK cells in the BM was detected ( Fig. 3 A ) . Surprisingly, only a minority of MHC-II + NK cells coexpressed B220, and in the tissues examined, MHC-II and B220 expression on NK cells was not correlated in an obvious fashion ( Fig. 3 A ) . Similar results were obtained when examining coexpression of B220 and CD86 on NK cells (unpublished data). These results argue against the existence of a widely distributed IKDC-like NK1.1 ϩ cell that coexpresses B220 and MHC-II ( 5, 6 ). The low frequency of MHC-II ϩ NK cells might refl ect the steady-state, noninfl ammatory situation in normal, healthy mice. We next analyzed whether infl ammatory stimuli would modify the NK cell phenotype in vivo. Mice were injected with either poly I:C (a Toll-like receptor [TLR] 3 ligand) or CpG ODN (a TLR9 ligand), and 3 d later, CD3 Ϫ NK1.1 ϩ cells were analyzed for CD11c, MHC-II, and B220. CD11c levels increased dramatically on NK cells from the BM, spleen, and lymph nodes after TLR activation ( Fig. 3 B ) . Concurrently, most NK cells up-regulated B220 expression. As a result, ‫ف‬ 30 -50% of NK cells from poly I:C -or CpG ODNtreated mice became IKDC-like ( Fig. 3 B ) . The increase in CD11c ϩ B220 ϩ NK cells was likely caused by up-regulation of these markers rather than by preferential proliferation of CD11c lo B220 ϩ NK1.1 + cells, because Ki67 expression (a marker of cells undergoing cell division) was predominantly found in NK1.1 ϩ B220 neg cells (unpublished data). Interestingly, MHC-II expression was increased on all NK cells in mice treated with CpG ODN but only in lymph node NK cells in mice receiving poly I:C treatment ( Fig. 3 C ) , suggesting a diff erential threshold for induction of MHC-II on NK cells after activation in this tissue. As for the case with resting NK cells ( Fig. 3 A ) , no direct correlation could be made with inducible MHC-II expression in NK cells expressing diff erent levels of B220 (not depicted). These results suggested that CD11c, B220, and MHC-II behave as classical activation markers on NK cells, although their inducible expression is diff erentially controlled. Finally, increased CD86 expression paralleled inducible MHC-II expression (unpublished data). Collectively, these results show that mouse NK cells appear to closely resemble human NK cells in their inducible expression of MHC-II and co-stimulatory molecules ( 20 ) .
NKp46 is an NK cell -specifi c receptor expressed in human, bovine, and mouse NK cells encoded by the Ncr-1 gene ( 14, 16 -18 ) . Mice expressing GFP under Ncr-1 transcriptional control elements show strong GFP fl uorescence in CD3 Ϫ NK1.1 ϩ cells ( 14, 18 ) . Using Ncr-1 gfp/ϩ mice ( 14 ), we found that two cell types were present in the CD3 Ϫ CD19 − CD11c lo B220 + subset: the fi rst consisted of pDCs that expressed the pDC antigen 1 (PDCA-1) marker, whereas the second included the putative IKDCs expressing NK1.1 ( Fig. 1 C ) . Remarkably, the CD11c lo B220 ϩ NK1.1 ϩ subset highly expressed NKp46 (also confi rmed by cell-surface staining; unpublished data), indicating that IKDC-like cells were more closely related to NK cells than previously anticipated. Moreover, NKp46 expression was completely eliminated when Ncr-1 gfp/ϩ mice were made deficient in ␥ c ( Fig. 1 C ) . NKp46 expression was not detected in pDCs ( Fig. 1 C ) or conventional DCs (cDCs; not depicted) under any condition.
A recent report indicated that IKDCs in ␥ c -defi cient mice diff ered from IKDCs in C57BL/6 mice in that they were NK1.1 Ϫ but expressed CD49b ( 19 ) . We therefore studied the NK1.1 Ϫ CD49b ϩ cells that were equally present in the BM of Rag2 Ϫ / Ϫ , Rag2 Ϫ / − IL-2R ␤ Ϫ / Ϫ , and Rag2 Ϫ / Ϫ ␥ c Ϫ /y mice ( Fig.  1 D ) . Compared with NK1.1 ϩ CD49 ϩ cells (of which a fraction expressed the CD11c lo B220 ϩ phenotype), NK1.1 Ϫ CD49b ϩ cells lacked CD11c and B220 expression ( Fig. 1 C ) . Thus, NK1.1 ϩ cells with the CD11c lo B220 ϩ phenotype (IKDC-like cells) require IL-15 for their development and express NKp46; these are characteristics of bone fi de NK cells.
B220 expression on developing and mature NK cells
We studied further the expression of B220 by cells of the NK cell lineage. NK cell precursors were essentially B220 Ϫ , whereas a minor population of immature NK cells were B220 lo ( Fig. 2 A ) . In contrast, ‫ف‬ 10-30% of mature NK1.1 ϩ CD49b ϩ NK cells in the BM and spleen clearly expressed B220 in a rather homogeneous fashion ( Fig. 2, A and B ) . Because B220 expression on peripheral NK cells was not bimodal, we consider it arbitrary to designate B220 Ϫ versus B220 ϩ NK cell subsets, as others have done ( 5, 6 ) . Examining the phenotypes of NK1.1 ϩ cells bearing low versus high levels of B220 ( Fig. 2 B ) , the frequency of NK cells expressing Ly49 receptors (A, C/I, G2, or D) or CD94 was not substantially diff erent. B220 ϩ NK cells were uniformly CD62L hi and had slightly higher expression of CD11c ( Fig. 2 B ) , although CD11c expression was not bimodal. In contrast, the overall density of CD11b was reduced on B220 ϩ NK cells. No diff erences in the expression of NKG2D, CD49b, and CD44 were found between B220 Ϫ and B220 ϩ NK cells (unpublished data).
Previous reports have demonstrated that B220 ϩ NK cells have enhanced functional activities compared with B220 Ϫ NK cells ( 5, 6 ) . We found that both B220 Ϫ and B220 ϩ NK cells were similarly capable of IFN-␥ production after stimulation in vitro with IL-2 and IL-12 or IL-2 and CpG oligodeoxynucleotide (ODN; Fig. 2 C ) . Moreover, IFN-␥ production did not correlate with CD11c expression ( Fig. 2 C ) . However, when stimulated with pharmacological agents BRIEF DEFINITIVE REPORT 
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was accompanied by an increase in B220 expression (a twofold increase in mean fl uorescence intensity). By days 3 and 4, a clear fraction of NK cells had further proliferated, and their B220 expression was approximately fi vefold higher than that observed on NK cells at the start of the culture. Similar results were obtained in IL-2 -supplemented cultures of lymph nodeor thymus-derived NK cells ( Fig. 4 A and not depicted) . All IL-2 -cultured NK cells demonstrated increased expression of NK1.1, CD11c, and B220 (unpublished data), suggesting that
NK cell proliferation increases B220 expression in vitro and in vivo
To understand the mechanisms and dynamics of inducible B220 expression by NK1.1 ϩ cells, we labeled total splenocytes from Rag2 Ϫ / Ϫ mice with CFSE and cultured them in IL-2. B220 expression on NK1.1 ϩ cells was analyzed daily in relation to cytokine-induced proliferation. During the fi rst 2 d, most NK cells divided asynchronously, as indicated by the even dilution of CFSE in the bulk NK cell population, which T cell stimulatory activity of B220 ؉ and B220 ؊ NK cells Peptide-pulsed CD11c lo B220 ϩ NK1.1 + cells were reported to stimulate antigen-specifi c T cells ( 5 ) , suggesting that IKDCs could function as APCs to stimulate adaptive immune responses. We next assessed whether T cell stimulatory activity was a unique property of B220 ϩ NK cells. " Marilyn " TCRtransgenic cells specifi c for the male antigen Dby presented by I-A b ( 24 ) were used as responder cells. Female Rag2 Ϫ / Ϫ mice were injected with CpG ODN, and 3 d later, B220 ϩ NK cells, B220 Ϫ NK cells, pDCs, and cDCs were isolated. Cells were pulsed with the Dby peptide, and pulsed and nonpulsed cells were cultured with sorted, CFSE-labeled Marilyn T cells. After 5 d, T cell proliferation was assessed by CFSE dilution. Both B220 ϩ and B220 Ϫ NK cells were able to stimulate division of ‫ف‬ 30% of Marilyn CD4 ϩ T cells ( Fig. 5 ) . Nevertheless, CpG-activated NK cells were clearly less effi cient than either pDCs or cDCs in their T cell stimulatory capacity. This result contrasts with a previous study that demonstrated B220 ϩ NK cells to be more effi cient than pDCs in T cell stimulation ( 5 ) . The diff erence may lie in the choice of a TCRtransgenic mouse model (OT-II vs. Marilyn) that may diff er in activation threshold.
Conclusions
In this report, we provide evidence that NK1.1 ϩ cells with the CD11c lo B220 ϩ phenotype (IKDC-like cells) are bona fi de NK cells. All CD3 Ϫ NK1.1 + cells share the same developmental requirements ( ␥ c , IL-2R ␤ , and IL-15) and express the same NK cell -specifi c genes (NKp46). These features clearly distinguish NK cells from diverse DC subsets.
We also demonstrate inducible B220 and CD11c expression after NK cell activation in vitro and in vivo. The capacity of NK cells to express high levels of CD11c after activation in vivo might explain the increased frequency of intratumoral CD11c ϩ NK1.1 ϩ cells detected in patients treated with imatinib mesylate and IL-2, as reported by Taieb et al. ( 6 ) . Similarly, their activated status would explain why B220 ϩ NK1.1 + cytokine-induced proliferation can generate an IKDC-like phenotype from resting NK cells.
To study whether B220 ϩ NK cells can up-regulate this protein after activation, we sorted splenic B220 ϩ and B220 − NK cells (NK1.1 ϩ CD49b ϩ ) from Rag2 − / − mice and cultured them with IL-2. At day 7, we found that all NK cells from the sorted B220 Ϫ population now expressed B220 at the cell surface at levels similar to the sorted B220 ϩ population ( Fig. 4 B ) .
To further investigate the proliferation-induced B220 expression on NK cells, we purifi ed splenic B220 − and B220 ϩ NK1.1 ϩ cells from Rag2 − / − mice, labeled them with CFSE, and adoptively transferred them into NK cell -defi cient Rag2 − / Ϫ IL-2R ␤ − / − recipient mice. The analysis of CD11c expression by the sorted B220 − and B220 ϩ NK cells confi rmed that both populations expressed CD11c, with B220 ϩ NK cells expressing slightly higher CD11c levels (Fig. S2 , available at http://www.jem.org/cgi/content/full/jem.20071451/DC1). Both NK cell populations underwent " homeostatic " proliferation ( 21 -23 ) based on their CFSE-dilution profi les. Although B220 + NK cells maintained B220 expression, the B220 − NK cells became B220 + ( Fig. 4 C ) . We next assessed whether B220 induction on B220 − NK cells was proliferation dependent by transferring CFSE-labeled B220 − and B220 ϩ NK cells into NK cell -profi cient (B − , T − , and NK ϩ ) Rag2 − / − recipients. Most transferred NK cells did not divide in these hosts ( Fig. 4 C ) , likely because of competition with endogenous NK cells for cellular resources such as IL-15 ( 22 ) . Under these conditions, B220 − NK cells remained B220 Ϫ , whereas B220 ϩ NK cells maintained B220 expression ( Fig. 4 C ) . Lastly, we assessed the eff ects of TLR engagement on the fate of adoptively transferred B220 Ϫ NK cells in Rag2 Ϫ / Ϫ recipients. In contrast to untreated Rag2 Ϫ / − mice, B220 Ϫ NK cells proliferated in poly I:C -treated Rag2 Ϫ / Ϫ recipients, with concomitant upregulation of B220 expression ( Fig. 4 C ) . Thus, B220 expression is up-regulated on proliferating NK cells in vivo. These results suggest that TLR ligands may modify NK cell activation states through stimulation of NK cell proliferation. 
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cells isolated from these patients exhibit an increased functional competence in vitro and in vivo ( 6 ) . Other markers suggested to be specifi c for CD11c lo B220 ϩ NK1.1 ϩ cells, such as MHC-II and CD86, were clearly not confi ned to these cells but were also expressed by B220 lo/ − NK cells in naive mice. Some of these activation-induced phenotypic changes (acquisition of B220) are closely linked to cellular proliferation. Up-regulation of B220 and CD11c has been previously detected on activated NK T cells and CD8 + T cells ( 10, 25 ) . As such, these " atypical " markers may signal recent cytokine stimulation, thereby representing a conserved mechanism that operates in cytotoxic cells.
MATERIALS AND METHODS

Mouse strains. Mice defi cient in
on the C57BL/6 background have been previously described ( 15, 26 ) . Mice carrying a GFP reporter in the NK cell -specifi c Ncr-1 locus ( Ncr1 gfp/ϩ ) have been previously described ( 14 ) , and male Ncr1 gfp/ϩ mice were crossed to female Rag2 Ϫ / Ϫ ␥ c Ϫ / Ϫ mice to create ␥ c -defi cient Ncr1 gfp/ϩ male mice. C57BL/6 mice were obtained from Charles River Laboratories. Mice were maintained in specifi c pathogen-free conditions at the Institut Pasteur and were used at 4 -10 wk of age. Mouse experiments were approved by an institutional committee at the Institut Pasteur and validated by the French Ministry of Agriculture.
Antibodies and reagents. mAbs directly conjugated to FITC, PE, PECy7, PerCP-Cy5.5, PE-Cy5.5, allophycocyanin, allophycocyanin-Cy7, or biotin specifi c for the following antigens (clone name in parenthesis) were used: B220 (RA3-6B2), CD3 (145-2C11), CD11b (M1/70), CD11c (N418 and HL3, respectively), CD19 (1D3), CD49b (DX5), CD62L (MEL14), CD86 (GL1), CD94 (18d3), CD122 (TM-␤ 1), I-A/I-E (M5/1 14.15.2), Ly49A (JR9), Ly49G2 (4D11), Ly49C/I (5E6), NK1.1 (PK136), PDCA-1 (PDCA-1), and IFN-␥ (XMG1.2). Antibodies were purchased from Becton Dickinson, eBioscience, Biolegend, and Miltenyi Biotec. The polyclonal goat anti -mouse anti-NKp46 serum was purchased from R & D Systems. FCS and PBS were purchased from Invitrogen.
Isolation of lymphoid cells and fl ow cytometric analysis. Single-cell suspensions from the BM, spleen, lymph nodes, and thymus and FACS analysis were performed using a fl ow cytometer (FACSCanto or FACSCanto II; Becton Dickinson) with FACSDiva software (5.02; Becton Dickinson), as previously described ( 27 ) . Datasets were analyzed using FlowJo software (Tree Star, Inc.). Cell sorting was performed on a cell sorter (FACSAria, BD Biosciences; access was provided by the Flow Cytometry Platform at the Institut Pasteur).
Adoptive transfer of sorted NK cell subpopulations. Splenic cell suspensions from Rag2 Ϫ / − mice were sorted as NK1.1 + CD49b + B220 ϩ or B220 Ϫ cells and injected i.v. into alymphoid recipients. At the given times after transfer (as shown in the fi gures), splenic lymphocytes were prepared, and their phenotype was determined. Alternatively, cells were labeled with CFSE after sorting, injected i.v. into Rag2 Ϫ / Ϫ or Rag2 Ϫ / Ϫ IL-2R ␤ Ϫ / Ϫ mice, and analyzed 3 d later.
In vitro cultures. Splenic cell suspensions from Rag2 Ϫ / Ϫ mice were labeled with 5 m CFSE, and 1 -2 ϫ 10 5 cells per 200 l were cultured in fl at-bottom microtiter plates in 1,000 U/ml IL-2 (PeproTech). For co-cultures of Marilyn T cells with NK cells or IKDC-like cells, we sorted NK1.1 + B220 − and NK1.1 + B220 + cells from female Rag2 Ϫ / Ϫ mice and incubated half of the sorted cells with 100 nM Dby peptide. 2 ϫ 10 4 of the sorted cells were cultured with CFSE-labeled V ␤ 6 + CD4 + T cells from Marilyn Rag2 Ϫ / Ϫ transgenic mice ( 28 ) at a 1:1 ratio. As controls, we co-cultured Marilyn T cells with sorted NK1.1 + B220 Ϫ and NK1.1 ϩ B220 + cells that had not been incubated with peptide, and with sorted pDCs and cDCs from the same female Rag2 Ϫ / Ϫ mice. CpG ODN -activated cells were obtained from Rag2 Ϫ / Ϫ mice that received 35 g CpG ODN (i.p.) 3 d earlier.
In vivo activation. Rag2 Ϫ / Ϫ or C57BL/6 mice were injected i.p. with either CpG ODN 1668 (S-oligo; Sigma-Proligo) or poly I:C (Sigma-Aldrich). At the time points indicated in the fi gures, cells from the indicated organs were isolated and analyzed.
Online supplemental material. Fig. S1 shows an overlay of NK1.1 + CD49b + NK cells on a CD11c versus B220 dot plot of viable BM cells derived from Rag2 − / − , Rag2 − / − IL-2 − / − , and Rag2 − / − IL-15 − / − mice. Fig. S2 shows the expression of B220 and CD11c by sorted B220 + and B220 − NK1.1 + CD49b + splenocytes from Rag2 − / − mice. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20071451/DC1.
